Compass Therapeutics (NASDAQ:CMPX) is a biotechnology firm deeply immersed in the discovery and development of antibody therapeutics aimed at treating cancer, autoimmune disorders, and other diseases. The company leverages its proprietary StitchMabs™ and common light chain platforms to engineer novel biologic agents. Compass Therapeutics focuses on advancing its robust pipeline of therapeutic candidates, including lead assets that show promising preclinical and early clinical results for a range of medical conditions. The ultimate objective of Compass Therapeutics is to transform the landscape of treatment options available to patients suffering from severe diseases by bringing innovative and effective therapies to market.